@article{ref1,
title="Usefulness of bone density measurement in fallers",
journal="Joint Bone Spine: Revue du Rhumatisme",
year="2014",
author="Blain, Hubert and Rolland, Yves and Beauchet, Olivier and Annweiler, Cédric and Benhamou, Claude-Laurent and Benetos, Athanase and Berrut, Gilles and Audran, Maurice and Bendavid, Sauveur and Bousson, Valérie and Briot, Karine and Brazier, Michel and Breuil, Véronique and Chapuis, Laure and Chapurlat, Roland and Cohen-Solal, Martine and Cortet, Bernard and Dargent, Patricia and Fardellone, Patrice and Feron, Jean-Marc and Gauvain, Jean-Bernard and Guggenbuhl, Pascal and Hanon, Olivier and Laroche, Michel and Kolta, Sami and Lespessailles, Eric and Letombe, Brigitte and Mallet, Eric and Marcelli, Christian and Orcel, Philippe and Puisieux, Francois and Seret, Patrick and Souberbielle, Jean-Claude and Sutter, Bruno and Trémollières, Florence and Weryha, Georges and Roux, Christian and Thomas, Thierry",
volume="81",
number="5",
pages="403-408",
abstract="The objective of this systematic literature review is to discuss the latest French recommendation issued in 2012 that a fall within the past year should lead to bone mineral density (BMD) measurement using dual-energy X-ray absorptiometry (DXA). This recommendation rests on four facts. First, osteoporosis and fall risk are the two leading risk factors for nonvertebral fractures in postmenopausal women. Second, BMD measurement using DXA supplies significant information on the fracture risk independently from the fall risk. Thus, when a fall occurs, the fracture risk increases as BMD decreases. Third, osteoporosis drugs have been proven effective in preventing fractures only in populations with osteoporosis defined based on BMD criteria. Finally, the prevalence of osteoporosis is high in patients who fall and increases in the presence of markers for frailty (e.g., recurrent falls, sarcopenia [low muscle mass and strength], limited mobility, and weight loss), which are risk factors for both osteoporosis and falls. Nevertheless, life expectancy should be taken into account when assessing the appropriateness of DXA in fallers, as osteoporosis treatments require at least 12months to decrease the fracture risk. Another relevant factor is the availability of DXA, which may be limited due to geographic factors, patient dependency, or severe cognitive impairments, for instance. Studies are needed to better determine how the fall risk and frailty should be incorporated into the fracture risk evaluation based on BMD and the FRAX(®) tool.<p /> <p>Language: en</p>",
language="en",
issn="1297-319X",
doi="10.1016/j.jbspin.2014.01.020",
url="http://dx.doi.org/10.1016/j.jbspin.2014.01.020"
}